Finanzen von Zymeworks Inc (ZYME)ZYMEZymeworks Inc

Evaluating the bottom line, Zymeworks Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -918.95%, while the net margin is -980.81%. These profitability ratios, combined with a Return on Equity (ROE) of -72.31%, provide a clear picture of how effectively ZYME converts its operational activities into shareholder value.

In the context of the broader market, ZYME competes directly with industry leaders such as SRPT and AGIO. With a market capitalization of $1.80B, it holds a significant position in the sector. When comparing efficiency, ZYME's gross margin of 100.00% stands against SRPT's 62.59% and AGIO's 93.30%. Such benchmarking helps identify whether Zymeworks Inc. is trading at a premium or discount relative to its financial performance.

Zymeworks has shown a volatile financial performance with a recent net income loss of $45 million in Q2 2026, but it has also reported strong revenue growth expectations, with 2026 revenue guidance between $278 million and $292 million following the acquisition of Theravance Biopharma.